Nuvectis Pharma Inc
NASDAQ:NVCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nuvectis Pharma Inc
Other Long-Term Assets
Nuvectis Pharma Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nuvectis Pharma Inc
NASDAQ:NVCT
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$10.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
25%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$6.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$12.7B
|
CAGR 3-Years
29%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$4.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
35%
|
CAGR 10-Years
64%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$5.9B
|
CAGR 3-Years
43%
|
CAGR 5-Years
44%
|
CAGR 10-Years
29%
|
|
Nuvectis Pharma Inc
Glance View
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. The company is headquartered in Fort Lee, New Jersey and currently employs 8 full-time employees. The company went IPO on 2022-02-04. The firm focuses on the development of precision medicines for the treatment of unmet medical needs in oncology. The company uses target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Its product pipeline consists of NXP800 and NXP900. The firm's lead product candidate, NXP800 is a clinical-stage, oral small-molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. The company targets ovarian clear cell carcinoma (OCCC) and endometrioid ovarian cancer. NXP800 uses a synthetic lethality strategy to reduce the protective factors in the cell that are modified by overactivation of HSP1, with ARID1a gene defective cells being vulnerable. NXP900 is an oral small molecule designed to inhibit the roto-oncogene tyrosine-protein kinase (SRC) and YES1 kinases. The company is used for the treatment of SRC-associated solid tumors.
